IBDEI0RO ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12458,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Lt Eye,Severe Stage
 ;;^UTILITY(U,$J,358.3,12458,1,4,0)
 ;;=4^H40.1123
 ;;^UTILITY(U,$J,358.3,12458,2)
 ;;=^5138544
 ;;^UTILITY(U,$J,358.3,12459,0)
 ;;=H40.1124^^49^601^10
 ;;^UTILITY(U,$J,358.3,12459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12459,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Lt Eye,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,12459,1,4,0)
 ;;=4^H40.1124
 ;;^UTILITY(U,$J,358.3,12459,2)
 ;;=^5138545
 ;;^UTILITY(U,$J,358.3,12460,0)
 ;;=H40.1130^^49^601^8
 ;;^UTILITY(U,$J,358.3,12460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12460,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Bilateral,Stage Unspec
 ;;^UTILITY(U,$J,358.3,12460,1,4,0)
 ;;=4^H40.1130
 ;;^UTILITY(U,$J,358.3,12460,2)
 ;;=^5138546
 ;;^UTILITY(U,$J,358.3,12461,0)
 ;;=H40.1131^^49^601^6
 ;;^UTILITY(U,$J,358.3,12461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12461,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Bilateral,Mild Stage
 ;;^UTILITY(U,$J,358.3,12461,1,4,0)
 ;;=4^H40.1131
 ;;^UTILITY(U,$J,358.3,12461,2)
 ;;=^5138547
 ;;^UTILITY(U,$J,358.3,12462,0)
 ;;=H40.1132^^49^601^7
 ;;^UTILITY(U,$J,358.3,12462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12462,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Bilateral,Moderate Stage
 ;;^UTILITY(U,$J,358.3,12462,1,4,0)
 ;;=4^H40.1132
 ;;^UTILITY(U,$J,358.3,12462,2)
 ;;=^5138548
 ;;^UTILITY(U,$J,358.3,12463,0)
 ;;=H40.1133^^49^601^9
 ;;^UTILITY(U,$J,358.3,12463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12463,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Bilateral,Severe Stage
 ;;^UTILITY(U,$J,358.3,12463,1,4,0)
 ;;=4^H40.1133
 ;;^UTILITY(U,$J,358.3,12463,2)
 ;;=^5138549
 ;;^UTILITY(U,$J,358.3,12464,0)
 ;;=H40.1134^^49^601^5
 ;;^UTILITY(U,$J,358.3,12464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12464,1,3,0)
 ;;=3^Glaucoma,Primary Open-Angle,Bilateral,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,12464,1,4,0)
 ;;=4^H40.1134
 ;;^UTILITY(U,$J,358.3,12464,2)
 ;;=^5138550
 ;;^UTILITY(U,$J,358.3,12465,0)
 ;;=B18.2^^49^602^10
 ;;^UTILITY(U,$J,358.3,12465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12465,1,3,0)
 ;;=3^Chr Viral Hepatitis C
 ;;^UTILITY(U,$J,358.3,12465,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,12465,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,12466,0)
 ;;=D12.6^^49^602^9
 ;;^UTILITY(U,$J,358.3,12466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12466,1,3,0)
 ;;=3^Benign Neop of Colon,Unspec
 ;;^UTILITY(U,$J,358.3,12466,1,4,0)
 ;;=4^D12.6
 ;;^UTILITY(U,$J,358.3,12466,2)
 ;;=^5001969
 ;;^UTILITY(U,$J,358.3,12467,0)
 ;;=D12.0^^49^602^8
 ;;^UTILITY(U,$J,358.3,12467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12467,1,3,0)
 ;;=3^Benign Neop of Cecum
 ;;^UTILITY(U,$J,358.3,12467,1,4,0)
 ;;=4^D12.0
 ;;^UTILITY(U,$J,358.3,12467,2)
 ;;=^5001963
 ;;^UTILITY(U,$J,358.3,12468,0)
 ;;=K63.5^^49^602^12
 ;;^UTILITY(U,$J,358.3,12468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12468,1,3,0)
 ;;=3^Colon Polyp
 ;;^UTILITY(U,$J,358.3,12468,1,4,0)
 ;;=4^K63.5
 ;;^UTILITY(U,$J,358.3,12468,2)
 ;;=^5008765
 ;;^UTILITY(U,$J,358.3,12469,0)
 ;;=D12.1^^49^602^7
 ;;^UTILITY(U,$J,358.3,12469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12469,1,3,0)
 ;;=3^Benign Neop of Appendix
 ;;^UTILITY(U,$J,358.3,12469,1,4,0)
 ;;=4^D12.1
 ;;^UTILITY(U,$J,358.3,12469,2)
 ;;=^5001964
 ;;^UTILITY(U,$J,358.3,12470,0)
 ;;=K64.9^^49^602^16
